MDxHealth SA (MDXH) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed MDxHealth SA (MDXH) over the past year, losing 8.1% versus a loss of 86.5%. TriSalus Life Sciences is the larger company by market cap ($250.0 million vs $56.3 million), about 4.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | TLSI |
|---|---|---|
| Share price | $0.5897 | $4.06 |
| Market cap | $56.27M | $249.99M |
| 1-day change | +1.58% | -1.69% |
| YTD return | -83.48% | -41.83% |
| 1-year return | -86.47% | -8.14% |
| 5-year return | — | -58.99% |
| EPS (TTM) | $-0.70 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $7.95 |
| 52-week low | $0.40 | $2.20 |
| Distance from 52-week high | -88.94% | -48.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +205.24% | +156.16% |
| Average volume | 5.69M | 274.82K |
| Shares outstanding | 95.42M | 61.57M |
| Employees | 364 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TriSalus Life Sciences is about 4.4 times larger than MDxHealth SA by market value ($249.99M vs $56.27M).
- TLSI has outperformed MDXH by 78.3 percentage points over the past year.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
MDXH vs TLSI FAQ
Which is bigger, MDxHealth SA or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $249.99M compared with $56.27M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, MDXH or TLSI?
TLSI returned -8.14% over the past 12 months, compared with -86.47% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and TriSalus Life Sciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.